

Supplemental information

**Using deep learning to detect patients at risk
for prostate cancer despite benign biopsies**


Bojing Liu, Yinxin Wang, Philippe Weitz, Johan Lindberg, Johan Hartman, Wanzhong Wang, Lars Egevad, Henrik Grönberg, Martin Eklund, and Mattias Rantalainen

Supplementary materials

Table S1. Sample distribution. Related to Figure 1.

	Training set (training and validation)	Held-out test set	p-value
Prostate cancer, N (%)			
No	546 (0.55)	133 (0.58)	
Yes	665 (0.45)	164 (0.45)	0.976 ¹
ISUP 1	325 (0.27)	78 (0.26)	
ISUP 2	121 (0.10)	32 (0.11)	
ISUP 3	51 (0.04)	12 (0.04)	
ISUP 4	127 (0.10)	32 (0.11)	
ISUP 5	41 (0.03)	10 (0.03)	0.999 ¹
Mean cancer length, mean(\pm SD)	0.43 (\pm 0.82)	0.41 (\pm 0.85)	0.434 ²
Maximum cancer length, mean(\pm SD)	2.67 (\pm 3.77)	2.58 (\pm 3.66)	0.462 ²
Age (mean\pmSD)	63.52 (\pm 5.30)	63.14 (\pm 5.37)	0.119 ²
PSA (ng/ml), N (%)			
[1,3)	361 (0.30)	91 (0.31)	
[3,5)	508 (0.42)	125 (0.42)	
[5,10)	256 (0.21)	63 (0.21)	
[10,1e+04)	86 (0.07)	18 (0.06)	0.934 ¹

1.Chisq test, 2. Mann-Whitney U test



eFigure 1. Flow-chart. Related to Figure 1.

Table S2. Sensitivity by the International Society of Urological Pathology (ISUP) grading at different specificity levels in held-out test set. Related to Figure 2.

Specificity	Sensitivity				
	ISUP 1	ISUP 2	ISUP 3	ISUP 4	ISUP 5
0.99	0.01	0.03	0.08	0.09	0.10
0.98	0.17	0.06	0.17	0.25	0.40
0.95	0.19	0.16	0.17	0.31	0.40
0.90	0.28	0.31	0.33	0.41	0.70




Table S3. Sensitivity by the International Society of Urological Pathology (ISUP) grading at different specificity levels in validation set. Related to Figure 2.

Specificity	Sensitivity				
	ISUP 1	ISUP 2	ISUP 3	ISUP 4	ISUP 5
0.99	0.04	0.05	0.07	0.20	0.20
0.98	0.11	0.10	0.21	0.40	0.30
0.95	0.27	0.19	0.21	0.40	0.50
0.90	0.36	0.33	0.36	0.47	0.60